Immune Repertoire Sequencing Market: Growth, Size, Share, and Trends
Immune Repertoire Sequencing Market by Product (Instrument, Software, Assay Kit & Reagent (TCR, BCR Kit)), Technology (Sequencing, Bioinformatics), Service (Data Analysis), Application (Research, Drug Discovery & Development) - Global Forecast to 2030
USD 0.56 BN
MARKET SIZE, 2030
CAGR 9.6%
(2025-2030)
369
REPORT PAGES
527
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global IRS market is expected to reach USD 0.56 billion by 2030, up from USD 0.35 billion in 2025, at a CAGR of 9.6% during the forecast period. Rapid technological advancements and growing demand for personalized and precision medicines drive the market. In addition, growing applications in autoimmune disease research, the increasing use of IRS in organ transplant monitoring, and a rising focus on immunotherapy also propel market growth. Moreover, the combination of AI and ML, along with the growing applications in vaccine development, is expected to open up significant prospects for market growth. Trade restrictions, regulations, and high capital investment needs present challenges to the market.
KEY TAKEAWAYS
- The North America immune repertoire sequencing market accounted for a 42.9% revenue share in 2024.
- By offerings, the services segment is expected to register the highest CAGR of 10.2%
- By technology (products), the sequencing technology segment is expected to register the highest CAGR of 9.7%
- By application, the research segment accounted for largest revenue share in 2024.
- By end user (products), the academic & research Institutes segment is expected to dominate the market.
- By end user (services), the pharmaceutical and biotechnology companies segment is expected to dominate the market.
- Company Illumina, Inc., Thermo Fisher Scientific Inc. and PacBio were identified as some of the star players in the immune repertoire sequencing market (global), given their strong market share and offerings footprint.
- Companies Celemics, Inc., MedGenome and iRepertoire, among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, highlighting their potential as emerging market players.
The IRS market is expected to grow during the forecast period, supported by factors such as advances in technology and the increasing demand for personalized and precision medicine, which are major factors fueling market expansion. Additionally, the market benefits from broader applications in autoimmune disease research, more widespread use of immune repertoire sequencing (IRS) in organ transplant monitoring, and heightened emphasis on immunotherapy. The integration of artificial intelligence and machine learning, combined with the rising role of these solutions in vaccine development, is expected to create notable opportunities for growth. On the other hand, challenges such as trade restrictions, regulatory hurdles, and significant capital investment requirements continue to present barriers within the market.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on consumers' business emerges from customer trends or disruptions. Hot belts are the clients of IRS product manufacturers, and target applications, along with IRS service providers, are the clients of the IRS product manufacturers. Shifts, which are changing trends or disruptions, will impact the revenues of end users. The revenue impact on end users will affect the revenue of hotbeds, which in turn will impact the revenues of IRS product manufacturers.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Increasing use of IRS in organ transplant monitoring
-
Increasing applications in autoimmune disease research
RESTRAINTS
Impact
Level
Level
-
Need for high capital investment
-
Limited clinical adoption and validation
OPPORTUNITIES
Impact
Level
Level
-
Integration of AI and ML into IRS
-
Increasing applications in vaccine development
CHALLENGES
Impact
Level
Level
-
Variations in regulatory frameworks and international trade dynamics
-
Lack of workflow and data standardization
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing use of immune repertoire sequencing in organ transplant monitoring
IRS technology has revolutionized post-operative monitoring in organ transplantation by providing unprecedented insights into the immune system. IRS can detect rejection episodes in kidney, liver, and heart transplants by analyzing peripheral blood T-cell receptor (TCR) and B-cell receptor (BCR) clonal expansions. The pre-transplant immunological profile shows that patients with higher baseline BCR diversity are more susceptible to rejection, allowing risk classification. The technology’s mixed lymphocyte culture and IRS analysis help identify antigen-specific alloreactive T-cell clones, enabling clinicians to personalize immunosuppressive regimens.
Restraint: Limited clinical adoption and validation
While the IRS shows great scientific promise, it has yet to be widely accepted and integrated into clinical practice. Moreover, many IRS-based tests and tools lack the rigorous validation needed to meet clinical and regulatory standards; this gap restricts the expansion of the IRS market, especially in high-value areas such as diagnostics, therapy monitoring, and personalized medicine. Regulatory bodies such as the FDA and EMA require robust clinical data before the approval of diagnostic devices.
Opportunity: Increasing applications in vaccine development
IRS has advanced vaccine research by testing adaptive immune responses and accelerating antigen discovery. Particularly in the higher range of neutralizing antibodies generated by S-protein vaccines against RBD-targeted approaches, the technique allowed for a complete evaluation of vaccine-induced antibody responses during the COVID-19 outbreak. Research revealing over 8,500 IgG1 clonotypes from recovered patients shows IRS can now detect neoantigens for cancer vaccines and test therapeutic antibodies at high throughput. Combining the technology with next-generation vaccine technologies, such as mRNA and viral vectors, creates a strong pipeline for rapid pathogen response.
Challenge: Variations in regulatory frameworks and international trade dynamics
Changing regulatory systems and international trade dynamics provide significant challenges for the IRS industry. The lack of consistent global standards for analyzing high-throughput sequencing (HTS) data limits its diagnostic applications and presents a significant challenge. Before sanctioning HTS-based decisions, regulatory authorities require robust quality assurance, which slows clinical implementation. Trade conflicts further present challenges to the market, as exemplified by China’s prohibition on Illumina sequencers, which compelled reliance on domestic substitutes such as BGI. Such limits hinder global competitiveness and create supply chain uncertainty.
Immune Repertoire Sequencing Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Short-read sequencing was a bottleneck for the university, which was overcome with PacBio's HiFi long-read workflow | Project timelines reduced from months to a single sequencing run | Annual publications more than doubled |
 |
Oxford Nanopore Technology (ONT) platform was used for full-length immune repertoire reconstruction and profiling at the transcriptome-level using long-read sequencing | Design quantitatively robust full-length IR sequencing (FLIRseq) method at the transcriptome level by integrating linear rolling circle amplification (RCA) with ONT techniques |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The IRS ecosystem involves identifying and analyzing the interconnected relationships among various stakeholders, including product manufacturers, service providers, and end users. The ecosystem for the IRS market comprises major CROs offering IRS products & services, regulatory authorities, and end users, such as pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. These stakeholders interact and collaborate to drive growth and innovation in the IRS market landscape.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Immune Repertoire Sequencing Market, By Offering
The product segment accounted for the largest market revenue share in 2024. The large share of this segment can be attributed to growing research in transplantation and immune rejection and immune-oncology conditions and the increasing adoption of instruments and consumables for diagnostic applications.
Immune Repertoire Sequencing Products Market, By Technology
The sequencing technology segment dominated the overall IRS market in 2024. This is largely due to the growing advancements in NGS offerings and increased research on immunotherapy discovery & development.
Immune Repertoire Sequencing Market, By Application
In 2024, research applications accounted for the largest share of the global IRS market, driven by the increasing focus on immune-oncology research, technological advancements in sequencing, and growing funding and academic interest.
REGION
Asia Pacific to be fastest-growing region in global IRS market during forecast period
The Asia Pacific graphene market is expected to register the highest CAGR during the forecast period. This is mainly driven by its rapidly developing healthcare sector, rising incidence of chronic diseases, and increasing governmental initiatives to promote immunology research. The increasing demand for precision diagnostics and therapies in emerging economies, such as China and India, is expected to drive market growth.
Immune Repertoire Sequencing Market: COMPANY EVALUATION MATRIX
In the IRS market matrix, Illumina, Inc. (Star) leads with a strong market presence and a wide portfolio of offerings, driving growing adoption across research, autoimmune, and immunotherapy applications. Agilent Technologies (Emerging Leader) is gaining traction with its enhanced position in the IRS space. While Illumina, Inc. dominates with scale, Agilent Technologies shows strong growth potential to advance toward the leaders' quadrant.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 0.34 Billion |
| Market Forecast in 2030 (Value) | USD 0.56 Billion |
| Growth Rate | CAGR of 9.6% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, the Middle East and Africa |
WHAT IS IN IT FOR YOU: Immune Repertoire Sequencing Market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| North America IRS Landscape |
|
|
| Service provider identification on North America and Europe | Identification of service providers in North America and Europe |
|
RECENT DEVELOPMENTS
- February 2025 : Nanopore and 10X Genomics collaborated for certified compatibility between 10x Genomics’ latest Chromium Universal GEM-X 3′ and GEM-X 5′ single-cell chemistries and Oxford Nanopore’s high-accuracy V14 chemistry.
- July 2024 : Illumina acquired Fluent BioSciences, a developer of an emerging and highly differentiated single-cell technology to help advance multi-omics growth strategies.
- December 2024 : PPD renewed two contracts with the US National Institutes of Health (NIH) to monitor clinical trial sites and provide research support for HIV and related diseases.
- Sep-23 : PacBio announced a partnership with Hamilton, Integra, Revvity, and Tecan to create fully automated protocols for preparing samples for sequencing on Revie and Sequel II and IIa systems.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
38
2
RESEARCH METHODOLOGY
42
3
EXECUTIVE SUMMARY
54
4
PREMIUM INSIGHTS
59
5
MARKET OVERVIEW
Immune repertoire sequencing surges with AI integration, driving personalized medicine and cancer immunotherapy.
62
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
INCREASING TECHNOLOGICAL ADVANCEMENTS
5.2.1.2
GROWING FOCUS ON PERSONALIZED/PRECISION MEDICINES
5.2.1.3
INCREASING USE OF IMMUNE REPERTOIRE SEQUENCING IN ORGAN TRANSPLANT MONITORING
5.2.1.4
INCREASING APPLICATIONS IN AUTOIMMUNE DISEASE RESEARCH
5.2.1.5
RISING FOCUS ON CANCER IMMUNOTHERAPY RESEARCH
5.2.2
RESTRAINTS
5.2.2.1
NEED FOR HIGH CAPITAL INVESTMENTS
5.2.2.2
LIMITED CLINICAL ADOPTION AND VALIDATION
5.2.3
OPPORTUNITIES
5.2.3.1
INTEGRATION OF AI AND ML INTO IMMUNE REPERTOIRE SEQUENCING
5.2.3.2
INCREASING APPLICATIONS IN VACCINE DEVELOPMENT
5.2.4
CHALLENGES
5.2.4.1
VARIATIONS IN REGULATORY FRAMEWORKS AND INTERNATIONAL TRADE DYNAMICS
5.2.4.2
LACK OF WORKFLOW AND DATA STANDARDIZATION
5.3
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4
PRICING ANALYSIS
5.4.1
AVERAGE SELLING PRICE TREND OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER, 2022–2024
5.4.2
AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024
5.5
SUPPLY CHAIN ANALYSIS
5.6
VALUE CHAIN ANALYSIS
5.7
ECOSYSTEM ANALYSIS
5.7.1
ROLE IN ECOSYSTEM
5.7.1.1
PRODUCT PROVIDERS
5.7.1.2
SERVICE PROVIDERS
5.7.1.3
END USERS
5.7.1.4
REGULATORY BODIES
5.8
TECHNOLOGY ANALYSIS
5.8.1
KEY TECHNOLOGIES
5.8.1.1
HIGH-THROUGHPUT SEQUENCING
5.8.1.2
NANOPORE SEQUENCING
5.8.1.3
SINGLE-MOLECULE REAL-TIME (SMRT) SEQUENCING
5.8.2
COMPLEMENTARY TECHNOLOGIES
5.8.2.1
BIOINFORMATICS AND DATA ANALYSIS PLATFORMS
5.8.2.2
MULTIPLEX PCR
5.8.2.3
5’RACE
5.8.3
ADJACENT TECHNOLOGIES
5.8.3.1
MULTI-OMICS INTEGRATION
5.8.3.2
SPATIAL GENOMICS AND TRANSCRIPTOMICS
5.8.3.3
SINGLE-CELL SEQUENCING TECHNOLOGIES
5.9
PATENT ANALYSIS
5.10
TRADE DATA ANALYSIS
5.10.1
IMPORT DATA FOR HS CODE 3822, 2020−2024
5.10.2
EXPORT DATA FOR HS CODE 3822, 2020−2024
5.11
KEY CONFERENCES & EVENTS, 2025–2026
5.12
REGULATORY ANALYSIS
5.12.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12.2
REGULATORY FRAMEWORK
5.12.2.1
NORTH AMERICA
5.12.2.2
EUROPE
5.12.2.3
ASIA PACIFIC
5.13
PORTER’S FIVE FORCES ANALYSIS
5.13.1
THREAT OF NEW ENTRANTS
5.13.2
THREAT OF SUBSTITUTES
5.13.3
BARGAINING POWER OF BUYERS
5.13.4
BARGAINING POWER OF SUPPLIERS
5.13.5
INTENSITY OF COMPETITIVE RIVALRY
5.14
KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2
KEY BUYING CRITERIA
5.15
INVESTMENT & FUNDING SCENARIO
5.16
IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET
6
IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 58 Data Tables
99
6.1
INTRODUCTION
6.2
ASSAY KITS & REAGENTS
6.2.1
TCR KITS
6.2.1.1
HUMAN TCR KITS
6.2.1.2
MOUSE TCR KITS
6.2.2
BCR KITS
6.2.2.1
HUMAN BCR KITS
6.2.2.2
MOUSE BCR KITS
6.2.3
OTHER ASSAY KITS & REAGENTS
6.3
INSTRUMENTS & SOFTWARE
6.3.1
TECHNOLOGICAL ADVANCEMENTS IN TRANSLATIONAL RESEARCH AND COMPANION DIAGNOSTICS TO AUGMENT MARKET GROWTH
7
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 32 Data Tables
124
7.1
INTRODUCTION
7.2
SEQUENCING TECHNOLOGIES
7.2.1
BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES
7.2.1.1
INCREASING ADOPTION OF TCR SEQUENCING FOR INFLAMMATION-MEDIATED DISEASES TO SUPPORT SEGMENT GROWTH
7.2.2
SINGLE-CELL SEQUENCING TECHNOLOGIES
7.2.2.1
NEED FOR INTEGRATIVE ANALYSIS OF IMMUNE RECEPTOR REPERTOIRES AND TRANSCRIPTIONAL STATES TO SPUR MARKET GROWTH
7.3
LIBRARY PREPARATION TECHNOLOGIES
7.3.1
HIGH DEMAND FOR COST-EFFICIENT AND HIGH-THROUGHPUT IMMUNE REPERTOIRE PROFILING TO FUEL MARKET GROWTH
7.4
BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES
7.4.1
GROWING FOCUS ON RESEARCH TO DRIVE DEMAND FOR ADVANCED BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES
8
IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 19 Data Tables
138
8.1
INTRODUCTION
8.2
SEQUENCING SERVICES
8.2.1
RISING NEED FOR HIGH-RESOLUTION IMMUNE PROFILING IN CANCER AND AUTOIMMUNE DISEASES TO DRIVE MARKET
8.3
DATA ANALYSIS SERVICES
8.3.1
HIGH DEMAND FOR STANDARDIZED NGS DATA INTERPRETATION AND CROSS-SAMPLE COMPARABILITY TO DRIVE MARKET
8.4
PRE-SEQUENCING SERVICES
8.4.1
INCREASED REQUIREMENT FOR STANDARDIZED WORKFLOWS FOR ADDRESSING PCR BIAS TO AUGMENT MARKET GROWTH
9
IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 19 Data Tables
147
9.1
INTRODUCTION
9.2
RESEARCH APPLICATIONS
9.2.1
LOW SEQUENCING COSTS AND INCREASED NEED TO RESOLVE CELLULAR HETEROGENEITY AT HIGH RESOLUTION TO DRIVE MARKET
9.3
DRUG DISCOVERY & DEVELOPMENT
9.3.1
INCREASED NEED FOR TARGETED THERAPIES AND ADVANCEMENTS IN HIGH-THROUGHPUT SCREENING TO AID MARKET GROWTH
9.4
CLINICAL DIAGNOSTICS
9.4.1
GROWING DEMAND FOR EARLY DETECTION OF SUBCLINICAL CONDITIONS TO AID MARKET GROWTH
10
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 19 Data Tables
157
10.1
INTRODUCTION
10.2
ACADEMIC & RESEARCH INSTITUTES
10.2.1
INCREASED FUNDING FOR IMMUNOLOGICAL RESEARCH AND IMMUNOGENOMICS TO DRIVE MARKET
10.3
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3.1
RISING FOCUS ON DRUG DISCOVERY AND THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH
10.4
OTHER END USERS
11
IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 19 Data Tables
167
11.1
INTRODUCTION
11.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1
NEED TO REDUCE IN-HOUSE INFRASTRUCTURE COSTS AND MEET SCALABILITY DEMANDS TO BOOST MARKET GROWTH
11.3
ACADEMIC & RESEARCH INSTITUTES
11.3.1
INCREASING FUNDING FOR GENOMIC RESEARCH AND GROWING DEMAND FOR COMPLEX DATA ANALYSIS TO AID MARKET GROWTH
11.4
OTHER END USERS
12
IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 14 Countries | 262 Data Tables.
177
12.1
INTRODUCTION
12.2
NORTH AMERICA
12.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2
US
12.2.2.1
US TO DOMINATE NORTH AMERICAN MARKET DURING FORECAST PERIOD
12.2.3
CANADA
12.2.3.1
PRESENCE OF ADVANCED RESEARCH FACILITIES AND FAVORABLE GOVERNMENT-FUNDED GENOMIC STUDIES TO SPUR MARKET GROWTH
12.3
EUROPE
12.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2
GERMANY
12.3.2.1
TECHNOLOGICAL ADVANCEMENTS IN RNA SEQUENCING TO FUEL MARKET GROWTH
12.3.3
UK
12.3.3.1
INCREASED CROSS-SECTOR PARTNERSHIPS AND ADVANCEMENTS IN AI TOOLS FOR LARGE SEQUENCING DATASETS TO BOOST MARKET GROWTH
12.3.4
FRANCE
12.3.4.1
PUBLIC-PRIVATE COLLABORATIONS AND INCREASED FUNDING FOR ADVANCED GENOMIC INFRASTRUCTURE TO AID MARKET GROWTH
12.3.5
ITALY
12.3.5.1
HIGH INVESTMENTS IN GENOMIC RESEARCH TO DRIVE MARKET
12.3.6
SPAIN
12.3.6.1
INCREASED GOVERNMENT INVESTMENTS IN PRECISION MEDICINE, GENOMIC MEDICINE, AND DATA SCIENCE TO PROPEL MARKET GROWTH
12.3.7
REST OF EUROPE
12.4
ASIA PACIFIC
12.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2
CHINA
12.4.2.1
RISING INCIDENCE OF CHRONIC DISEASES AND INCREASING COLLABORATIONS AMONG INDUSTRY STAKEHOLDERS TO DRIVE MARKET
12.4.3
JAPAN
12.4.3.1
INCREASING RESEARCH ON LONG-READ AND BIOMOLECULAR SEQUENCING TO AID MARKET GROWTH
12.4.4
INDIA
12.4.4.1
ADVANCEMENTS IN GENOMIC RESEARCH AND FOCUS ON INDUSTRY-ACADEMIA COLLABORATIONS TO EXPEDITE MARKET GROWTH
12.4.5
SOUTH KOREA
12.4.5.1
FAVORABLE GOVERNMENT INITIATIVES AND INVESTMENT IN SEQUENCING TECHNOLOGIES TO BOOST MARKET GROWTH
12.4.6
AUSTRALIA
12.4.6.1
INCREASED RESEARCH FUNDING AND FAVORABLE GOVERNMENT INITIATIVES TO DRIVE MARKET
12.4.7
REST OF ASIA PACIFIC
12.5
LATIN AMERICA
12.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2
BRAZIL
12.5.2.1
SUPPORTIVE REGULATORY FRAMEWORK FOR BIOTECHNOLOGY INNOVATION TO FUEL MARKET GROWTH
12.5.3
MEXICO
12.5.3.1
HIGH GERIATRIC POPULATION AND ADVANCEMENTS IN PRECISION MEDICINE RESEARCH TO SUPPORT MARKET GROWTH
12.5.4
REST OF LATIN AMERICA
12.6
MIDDLE EAST
12.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST
12.6.2
GCC COUNTRIES
12.6.2.1
FAVORABLE GOVERNMENT INITIATIVES TO DRIVE DRUG DEVELOPMENT AND CLINICAL RESEARCH
12.6.3
REST OF MIDDLE EAST
12.7
AFRICA
12.7.1
RISING GOVERNMENT FUNDING AND INCREASING INTERNATIONAL PARTNERSHIPS TO FAVOR MARKET GROWTH
12.7.2
MACROECONOMIC OUTLOOK FOR AFRICA
13
COMPETITIVE LANDSCAPE
Identify market leaders and emerging players reshaping industry dynamics with innovative strategies.
276
13.1
INTRODUCTION
13.2
KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022−2025
13.3
REVENUE ANALYSIS, 2022−2024
13.4
MARKET SHARE ANALYSIS, 2024
13.5
COMPANY VALUATION & FINANCIAL METRICS
13.5.1
COMPANY VALUATION
13.5.2
FINANCIAL METRICS
13.6
BRAND/PRODUCT COMPARISON
13.7
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.7.1
STARS
13.7.2
EMERGING LEADERS
13.7.3
PERVASIVE PLAYERS
13.7.4
PARTICIPANTS
13.7.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.7.5.1
COMPANY FOOTPRINT
13.7.5.2
REGION FOOTPRINT
13.7.5.3
PRODUCT AND SERVICE FOOTPRINT
13.7.5.4
APPLICATION FOOTPRINT
13.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.8.1
PROGRESSIVE COMPANIES
13.8.2
RESPONSIVE COMPANIES
13.8.3
DYNAMIC COMPANIES
13.8.4
STARTING BLOCKS
13.8.5
COMPETITIVE BENCHMARKING
13.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
13.8.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
13.9
COMPETITIVE SCENARIO
13.9.1
PRODUCT LAUNCHES/APPROVALS/UPGRADES
13.9.2
DEALS
13.9.3
EXPANSIONS
14
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
297
14.1
KEY PLAYERS
14.1.1
ILLUMINA, INC.
14.1.1.1
BUSINESS OVERVIEW
14.1.1.2
PRODUCTS/SERVICES/SOLUTIONS OFFERED
14.1.1.3
RECENT DEVELOPMENTS
14.1.1.4
MNM VIEW
14.1.2
THERMO FISHER SCIENTIFIC INC.
14.1.3
PACBIO
14.1.4
OXFORD NANOPORE TECHNOLOGIES PLC
14.1.5
10X GENOMICS
14.1.6
QIAGEN
14.1.7
AGILENT TECHNOLOGIES
14.1.8
DANAHER CORPORATION
14.1.9
TAKARA BIO INC.
14.1.10
ADAPTIVE BIOTECHNOLOGIES
14.1.11
BGI GROUP
14.1.12
TECAN TRADING AG
14.1.13
AZENTA US INC.
14.1.14
PERSONALIS, INC.
14.1.15
CREATIVE BIOLABS
14.2
OTHER PLAYERS
14.2.1
CELEMICS, INC.
14.2.2
CELLCARTA
14.2.3
IREPERTOIRE, INC.
14.2.4
NEW ENGLAND BIOLABS
14.2.5
CERBA RESEARCH
14.2.6
CEGAT GMBH
14.2.7
ELEMENT BIOSCIENCES
14.2.8
SEQALIS
14.2.9
SYNBIO TECHNOLOGIES
14.2.10
MEDGENOME
14.2.11
ENPICOM
15
APPENDIX
363
15.1
DISCUSSION GUIDE
15.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3
CUSTOMIZATION OPTIONS
15.4
RELATED REPORTS
15.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
IMMUNE REPERTOIRE SEQUENCING MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
TABLE 3
IMMUNE REPERTOIRE SEQUENCING MARKET: RISK ANALYSIS
TABLE 4
IMMUNE REPERTOIRE SEQUENCING MARKET: IMPACT ANALYSIS
TABLE 5
AVERAGE SELLING PRICE TREND OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)
TABLE 6
AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024 (USD)
TABLE 7
IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT PROVIDERS
TABLE 8
IMMUNE REPERTOIRE SEQUENCING MARKET: SERVICE PROVIDERS
TABLE 9
IMMUNE REPERTOIRE SEQUENCING MARKET: END USERS
TABLE 10
IMMUNE REPERTOIRE SEQUENCING MARKET: REGULATORY BODIES
TABLE 11
INNOVATIONS AND PATENT REGISTRATIONS, 2024–2025
TABLE 12
IMPORT DATA FOR HS CODE 3822, BY REGION, 2020−2024 (USD)
TABLE 13
EXPORT DATA FOR HS CODE 3822, BY REGION, 2020−2024 (USD)
TABLE 14
IMMUNE REPERTOIRE SEQUENCING MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
TABLE 15
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19
IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER’S FIVE FORCES
TABLE 20
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
TABLE 21
KEY BUYING CRITERIA FOR MAJOR END USERS (PRODUCTS MARKET)
TABLE 22
KEY BUYING CRITERIA FOR MAJOR END USERS (SERVICES MARKET)
TABLE 23
IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 24
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 25
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 26
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 27
EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 28
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 31
TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 32
TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 33
NORTH AMERICA: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 34
EUROPE: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 35
ASIA PACIFIC: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 36
LATIN AMERICA: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37
MIDDLE EAST: TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 38
HUMAN TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 39
NORTH AMERICA: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40
EUROPE: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 41
ASIA PACIFIC: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42
LATIN AMERICA: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43
MIDDLE EAST: HUMAN TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 44
MOUSE TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 45
NORTH AMERICA: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46
EUROPE: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47
ASIA PACIFIC: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48
LATIN AMERICA: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49
MIDDLE EAST: MOUSE TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 50
BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 51
BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 52
NORTH AMERICA: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 53
EUROPE: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54
ASIA PACIFIC: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55
LATIN AMERICA: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56
MIDDLE EAST: BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 57
HUMAN BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 58
NORTH AMERICA: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59
EUROPE: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 60
ASIA PACIFIC: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61
LATIN AMERICA: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62
MIDDLE EAST: HUMAN BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 63
MOUSE BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 64
NORTH AMERICA: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 65
EUROPE: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
ASIA PACIFIC: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 67
LATIN AMERICA: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68
MIDDLE EAST: MOUSE BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 69
OTHER ASSAY KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 70
NORTH AMERICA: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71
EUROPE: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72
ASIA PACIFIC: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73
LATIN AMERICA: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74
MIDDLE EAST: OTHER ASSAY KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 75
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION)
TABLE 76
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 77
EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION)
TABLE 81
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 82
SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 83
SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 84
NORTH AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86
ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87
LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88
MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 89
BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 90
NORTH AMERICA: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91
EUROPE: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92
ASIA PACIFIC: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93
LATIN AMERICA: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94
MIDDLE EAST: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 95
SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 96
NORTH AMERICA: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97
EUROPE: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98
ASIA PACIFIC: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99
LATIN AMERICA: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100
MIDDLE EAST: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 101
LIBRARY PREPARATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 102
NORTH AMERICA: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 103
EUROPE: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104
ASIA PACIFIC: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105
LATIN AMERICA: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106
MIDDLE EAST: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 107
BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 108
NORTH AMERICA: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109
EUROPE: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 110
ASIA PACIFIC: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 111
LATIN AMERICA: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
MIDDLE EAST: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 113
IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 114
SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 115
NORTH AMERICA: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 116
EUROPE: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117
ASIA PACIFIC: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118
LATIN AMERICA: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
MIDDLE EAST: SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 120
DATA ANALYSIS SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 121
NORTH AMERICA: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122
EUROPE: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123
ASIA PACIFIC: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124
LATIN AMERICA: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125
MIDDLE EAST: DATA ANALYSIS SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 126
PRE-SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 127
NORTH AMERICA: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128
EUROPE: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129
ASIA PACIFIC: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130
LATIN AMERICA: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131
MIDDLE EAST: PRE-SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 132
IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 133
IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 134
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135
EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 137
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 139
IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION)
TABLE 140
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 141
EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 144
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION)
TABLE 145
IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 146
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147
EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 148
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 151
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 152
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 153
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 154
EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 158
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 159
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 160
EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 164
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 165
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 166
EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 170
IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 171
IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 172
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173
EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 175
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 176
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 177
IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 178
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 179
EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 180
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 182
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 183
IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 184
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 185
EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 186
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 187
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 189
IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 190
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 191
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 192
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 193
NORTH AMERICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 194
NORTH AMERICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 195
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 196
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 197
NORTH AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 198
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 199
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 200
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 201
NORTH AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 202
US: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 203
US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 204
US: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 205
US: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 206
US: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 207
US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 208
US: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 209
US: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 210
US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 211
US: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 212
CANADA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 213
CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 214
CANADA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 215
CANADA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 216
CANADA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 217
CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 218
CANADA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 219
CANADA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 220
CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 221
CANADA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 222
EUROPE: KEY MACROECONOMIC INDICATORS
TABLE 223
EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 224
EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 225
EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 226
EUROPE: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 227
EUROPE: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 228
EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 229
EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 230
EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 231
EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 232
EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 233
EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 234
GERMANY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 235
GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 236
GERMANY: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 237
GERMANY: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 238
GERMANY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 239
GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 240
GERMANY: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 241
GERMANY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 242
GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 243
GERMANY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 244
UK: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 245
UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 246
UK: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 247
UK: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 248
UK: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 249
UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 250
UK: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 251
UK: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 252
UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 253
UK: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 254
FRANCE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 255
FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 256
FRANCE: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 257
FRANCE: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 258
FRANCE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 259
FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 260
FRANCE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 261
FRANCE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 262
FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 263
FRANCE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 264
ITALY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 265
ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 266
ITALY: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 267
ITALY: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 268
ITALY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 269
ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 270
ITALY: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 271
ITALY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 272
ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 273
ITALY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 274
SPAIN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 275
SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 276
SPAIN: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 277
SPAIN: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 278
SPAIN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 279
SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 280
SPAIN: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 281
SPAIN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 282
SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 283
SPAIN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 284
REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 285
REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 286
REST OF EUROPE: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 287
REST OF EUROPE: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 288
REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 289
REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 290
REST OF EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 291
REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 292
REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER,2023–2030 (USD MILLION)
TABLE 293
REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 294
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 295
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 296
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 297
ASIA PACIFIC: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 298
ASIA PACIFIC: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 299
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 300
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 301
ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 302
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 303
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 304
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 305
ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
TABLE 306
CHINA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 307
CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 308
CHINA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 309
CHINA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 310
CHINA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 311
CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 312
CHINA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 313
CHINA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 314
CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 315
CHINA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 316
JAPAN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 317
JAPAN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 318
JAPAN: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 319
JAPAN: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 320
JAPAN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 321
JAPAN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 322
JAPAN: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 323
JAPAN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 324
JAPAN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 325
JAPAN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 326
INDIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 327
INDIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 328
INDIA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 329
INDIA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 330
INDIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 331
INDIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 332
INDIA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 333
INDIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 334
INDIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 335
INDIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 336
SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 337
SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 338
SOUTH KOREA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 339
SOUTH KOREA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 340
SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 341
SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 342
SOUTH KOREA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 343
SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 344
SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 345
SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 346
AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 347
AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 348
AUSTRALIA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 349
AUSTRALIA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 350
AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 351
AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 352
AUSTRALIA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 353
AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 354
AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 355
AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 356
REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 357
REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 358
REST OF ASIA PACIFIC: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 359
REST OF ASIA PACIFIC: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 360
REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 361
REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 362
REST OF ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 363
REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 364
REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 365
REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 366
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 367
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 368
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 369
LATIN AMERICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 370
LATIN AMERICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 371
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 372
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 373
LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 374
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 375
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 376
LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 377
LATIN AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 378
BRAZIL: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 379
BRAZIL: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 380
BRAZIL: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 381
BRAZIL: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 382
BRAZIL: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 383
BRAZIL: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 384
BRAZIL: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 385
BRAZIL: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 386
BRAZIL: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 387
BRAZIL: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 388
MEXICO: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 389
MEXICO: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 390
MEXICO: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 391
MEXICO: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 392
MEXICO: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 393
MEXICO: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 394
MEXICO: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 395
MEXICO: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 396
MEXICO: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 397
MEXICO: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 398
REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 399
REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 400
REST OF LATIN AMERICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 401
REST OF LATIN AMERICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 402
REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 403
REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 404
REST OF LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 405
REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 406
REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 407
REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 408
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 409
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 410
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 411
MIDDLE EAST: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 412
MIDDLE EAST: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 413
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 414
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 415
MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 416
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 417
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 418
MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 419
MIDDLE EAST: KEY MACROECONOMIC INDICATORS
TABLE 420
GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 421
GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 422
GCC COUNTRIES: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 423
GCC COUNTRIES: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 424
GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 425
GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 426
GCC COUNTRIES: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 427
GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 428
GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 429
GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 430
REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 431
REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 432
REST OF MIDDLE EAST: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 433
REST OF MIDDLE EAST: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 434
REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 435
REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 436
REST OF MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 437
REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 438
REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 439
REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 440
AFRICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 441
AFRICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 442
AFRICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 443
AFRICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 444
AFRICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
TABLE 445
AFRICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 446
AFRICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 447
AFRICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 448
AFRICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 449
AFRICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 450
AFRICA: KEY MACROECONOMIC INDICATORS
TABLE 451
IMMUNE REPERTOIRE SEQUENCING MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2022−2025
TABLE 452
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: DEGREE OF COMPETITION, 2024
TABLE 453
IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET: DEGREE OF COMPETITION, 2024
TABLE 454
IMMUNE REPERTOIRE SEQUENCING MARKET: REGION FOOTPRINT
TABLE 455
IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT AND SERVICE FOOTPRINT
TABLE 456
IMMUNE REPERTOIRE SEQUENCING MARKET: APPLICATION FOOTPRINT
TABLE 457
IMMUNE REPERTOIRE SEQUENCING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 458
IMMUNE REPERTOIRE SEQUENCING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 459
IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 460
IMMUNE REPERTOIRE SEQUENCING MARKET: DEALS, JANUARY 2022–MARCH 2025
TABLE 461
IMMUNE REPERTOIRE SEQUENCING MARKET: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 462
ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 463
ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 464
ILLUMINA, INC.: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 465
ILLUMINA, INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 466
ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 467
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 468
THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 469
THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 470
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 471
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 472
PACBIO: COMPANY OVERVIEW
TABLE 473
PACBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 474
PACBIO: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 475
PACBIO: DEALS, JANUARY 2022–MARCH 2025
TABLE 476
PACBIO: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 477
OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
TABLE 478
OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS/SERVICES/ SOLUTIONS OFFERED
TABLE 479
OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 480
OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2022–MARCH 2025
TABLE 481
10X GENOMICS: COMPANY OVERVIEW
TABLE 482
10X GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 483
10X GENOMICS: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 484
QIAGEN: COMPANY OVERVIEW
TABLE 485
QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 486
QIAGEN: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 487
QIAGEN: DEALS, JANUARY 2022–MARCH 2025
TABLE 488
QIAGEN: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 489
AGILENT TECHNOLOGIES: COMPANY OVERVIEW
TABLE 490
AGILENT TECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 491
AGILENT TECHNOLOGIES: DEALS, JANUARY 2022–MARCH 2025
TABLE 492
AGILENT TECHNOLOGIES: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 493
DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 494
DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 495
DANAHER CORPORATION: DEALS, JANUARY 2022–MARCH 2025
TABLE 496
TAKARA BIO INC.: COMPANY OVERVIEW
TABLE 497
TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 498
TAKARA BIO INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 499
ADAPTIVE BIOTECHNOLOGIES: COMPANY OVERVIEW
TABLE 500
ADAPTIVE BIOTECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 501
BGI GROUP: COMPANY OVERVIEW
TABLE 502
BGI GROUP: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 503
BGI GROUP: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 504
BGI GROUP: DEALS, JANUARY 2022–MARCH 2025
TABLE 505
BGI GROUP: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
TABLE 506
TECAN TRADING AG: COMPANY OVERVIEW
TABLE 507
TECAN TRADING AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 508
TECAN TRADING AG: DEALS, JANUARY 2022–MARCH 2025
TABLE 509
AZENTA US INC.: COMPANY OVERVIEW
TABLE 510
AZENTA US INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 511
PERSONALIS, INC.: COMPANY OVERVIEW
TABLE 512
PERSONALIS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 513
PERSONALIS, INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 514
PERSONALIS, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
TABLE 515
CREATIVE BIOLABS: COMPANY OVERVIEW
TABLE 516
CREATIVE BIOLABS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 517
CELEMICS, INC.: COMPANY OVERVIEW
TABLE 518
CELLCARTA: COMPANY OVERVIEW
TABLE 519
IREPERTOIRE, INC.: COMPANY OVERVIEW
TABLE 520
NEW ENGLAND BIOLABS: COMPANY OVERVIEW
TABLE 521
CERBA RESEARCH: COMPANY OVERVIEW
TABLE 522
CEGAT GMBH: COMPANY OVERVIEW
TABLE 523
ELEMENT BIOSCIENCES: COMPANY OVERVIEW
TABLE 524
SEQALIS: COMPANY OVERVIEW
TABLE 525
SYNBIO TECHNOLOGIES: COMPANY OVERVIEW
TABLE 526
MEDGENOME: COMPANY OVERVIEW
TABLE 527
ENPICOM: COMPANY OVERVIEW
LIST OF FIGURES
FIGURE 1
IMMUNE REPERTOIRE SEQUENCING MARKET: SEGMENTS CONSIDERED & GEOGRAPHICAL SPREAD
FIGURE 2
IMMUNE REPERTOIRE SEQUENCING MARKET: YEARS CONSIDERED
FIGURE 3
IMMUNE REPERTOIRE SEQUENCING MARKET: RESEARCH DESIGN
FIGURE 4
IMMUNE REPERTOIRE SEQUENCING MARKET: BREAKDOWN OF PRIMARIES
FIGURE 5
IMMUNE REPERTOIRE SEQUENCING MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2024)
FIGURE 6
GLOBAL PRODUCTS MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024)
FIGURE 7
GLOBAL SERVICES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024)
FIGURE 8
IMMUNE REPERTOIRE SEQUENCING MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 9
IMMUNE REPERTOIRE SEQUENCING MARKET: TOP-DOWN APPROACH
FIGURE 10
IMMUNE REPERTOIRE SEQUENCING MARKET: CAGR PROJECTIONS
FIGURE 11
DATA TRIANGULATION METHODOLOGY
FIGURE 12
IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
FIGURE 13
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
FIGURE 14
IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2025 VS. 2030 (USD MILLION)
FIGURE 15
IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 16
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 17
IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 18
IMMUNE REPERTOIRE SEQUENCING MARKET: REGIONAL SNAPSHOT
FIGURE 19
INCREASING ADOPTION OF PERSONALIZED MEDICINES AND RISING FOCUS ON GENOMIC RESEARCH TO DRIVE MARKET
FIGURE 20
US AND ASSAY KITS & REAGENTS DOMINATED NORTH AMERICAN MARKET IN 2024
FIGURE 21
SEQUENCING TECHNOLOGIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2030
FIGURE 22
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO COMMAND LARGEST END USER MARKET SHARE IN 2025
FIGURE 23
CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030
FIGURE 24
IMMUNE REPERTOIRE SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 25
IMMUNE REPERTOIRE SEQUENCING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 26
AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER (2024)
FIGURE 27
AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024 (USD)
FIGURE 28
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 29
IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: VALUE CHAIN ANALYSIS
FIGURE 30
IMMUNE REPERTOIRE SEQUENCING MARKET: ECOSYSTEM ANALYSIS
FIGURE 31
PATENT APPLICATIONS FOR IMMUNE REPERTOIRE SEQUENCING (JANUARY 2015–DECEMBER 2024)
FIGURE 32
IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 33
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
FIGURE 34
KEY BUYING CRITERIA FOR MAJOR END USERS (PRODUCTS MARKET)
FIGURE 35
KEY BUYING CRITERIA FOR MAJOR END USERS (SERVICES MARKET)
FIGURE 36
FUNDING AND NUMBER OF PROJECTS AND SUB-PROJECTS BY NATIONAL INSTITUTES OF HEALTH, 2021–2025
FIGURE 37
IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET
FIGURE 38
NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET SNAPSHOT
FIGURE 39
ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET SNAPSHOT
FIGURE 40
REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET (2022−2024)
FIGURE 41
REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET (2022−2024)
FIGURE 42
MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, 2024
FIGURE 43
MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, 2024
FIGURE 44
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 45
EV/EBITDA OF KEY PLAYERS
FIGURE 46
IMMUNE REPERTOIRE SEQUENCING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 47
IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 48
IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY FOOTPRINT
FIGURE 49
IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 50
ILLUMINA, INC.: COMPANY SNAPSHOT
FIGURE 51
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
FIGURE 52
PACBIO: COMPANY SNAPSHOT
FIGURE 53
OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT
FIGURE 54
10X GENOMICS: COMPANY SNAPSHOT
FIGURE 55
QIAGEN: COMPANY SNAPSHOT
FIGURE 56
AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
FIGURE 57
DANAHER CORPORATION: COMPANY SNAPSHOT
FIGURE 58
TAKARA BIO INC.: COMPANY SNAPSHOT
FIGURE 59
ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT
FIGURE 60
TECAN TRADING AG: COMPANY SNAPSHOT
FIGURE 61
AZENTA US INC.: COMPANY SNAPSHOT
FIGURE 62
PERSONALIS, INC.: COMPANY SNAPSHOT
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global IRS market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The market for the companies offering IRS is arrived at by secondary data available through paid and unpaid sources, analyzing the product and service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives. Secondary data was analyzed to arrive at the overall size of the global IRS market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global IRS market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biotechnology companies, and experts from the supply side, such as C-level and D-level executives and managers. These interviews were conducted across major regions: North America, Europe, the Asia Pacific, and the Rest of the World (including Latin America, the Middle East, and Africa). This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the IRS market was estimated and validated through multiple approaches, such as the top-down and bottom-up approaches. These methods were also used extensively to estimate the size of various market subsegments.
- The research methodology used to estimate the market size includes the following:
- The key players in the immune repertoire sequencing market have been identified through extensive primary and secondary research.
- The revenues generated from the immune repertoire sequencing businesses of leading players in product and service offerings were determined separately through primary and secondary research.
- The sum of the product and service market was used to arrive at the total IRS global market size, which was further segmented into various segments.
- All percentage shares, splits, and breakdowns for respective market segments were determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Market Definition
Immune repertoire refers to the diverse collection of T-cell and B-cell receptors within the adaptive immune system, which enables pathogen recognition and targeted immune responses. The IRS market encompasses technologies, products, and services that analyze the diversity and functional dynamics of T-cell and B-cell receptor repertoires within the adaptive immune system.
This market includes instruments, software, assays, kits, and reagents for immune receptor profiling, alongside presequencing, sequencing, and data analysis services that support research applications, drug discovery & development, and clinical diagnostics utilizing advanced methods such as NGS and PCR by various end users.
Stakeholders
- CDMOs & CROs
- Pharmaceutical & Biopharmaceutical Companies
- Academic & Research Institutes
- Diagnostic Companies
- Venture Capitalists & Investors
- Market Research & Consulting Firms
- Government & Regulatory Associations
Report Objectives
- To define, describe, and forecast the IRS market based on product, products technology, service workflow, application, product end user, service end user, and region.
- To provide detailed information regarding the major factors influencing market growth (drivers, opportunities, and industry-specific challenges) along with the current trends
- To strategically analyze micromarkets1 concerning their growth trends, prospects, and contributions to the total IRS market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the revenue of market segments with respect to six major regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
- To profile key players and comprehensively analyze their market shares and core competencies2
- To track and analyze competitive developments in the IRS market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and R&D activities
- To track and analyze the impact of AI/Gen AI on the IRS market
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and service excellence strategy
Key Questions Addressed by the Report
What are the opportunities for growth in the IRS industry?
The integration of AI and ML in sequencing technologies and expanding IRS applications in vaccine development present significant growth opportunities.
Which applications dominated the IRS market in 2025?
Research applications held the largest share of the IRS market by therapy area in 2025.
Which products of the IRS market are expected to witness the highest growth during the forecast period?
Assay kits & reagents are expected to grow the most during the forecast period.
Which end-user segment is expected to witness the highest growth in the IRS services market in 2024?
Pharmaceutical & Biotechnology companies are expected to register the highest growth rate.
What is the IRS market size in 2025?
The global IRS market is expected to reach USD 560.5 million in 2030 from USD 354.6 million in 2025.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Immune Repertoire Sequencing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Before You Go
Expand Beyond Immune Repertoire Sequencing Market
Explore the top 20 industries influencing your market growth
Human and AI Powered Market Intelligence
Find Untapped Markets
Growth opportunities and latent adjacency in Immune Repertoire Sequencing Market